Insider trading

Period: 120 months Stock: REGN + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

445 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

445 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

445 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

445 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
445 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
445 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

445 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
22 Aug 2018
BROWN MICHAEL S Director
Sold, plan not stated
$570.74K 1,500 at 380.49
100%
Sold half or more
2 Aug 2018
Sold, plan not stated
$760.00K 2,000 at 380.00
14.3%
10 Jul 2018
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 8×
$27.42M 74,670 at 367.22
15.7%
6 Jul 2018
Sold, plan not stated
$740.00K 2,000 at 370.00
14.3%
5 Jul 2018
Sold, plan not stated
$720.00K 2,000 at 360.00
14.3%
21 Jun 2018
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 13×
$24.50M 74,710 at 327.87
15.7%
8 Jun 2018
Sanofi 10% owner · indirect
Sold, plan not stated
$37.61M 121,601 at 309.31
0.5%
24 May 2018
STAHL NEIL EVP Research and Development
Sold, plan not stated
$3.37M 11,407 at 295.09
26.3%
10 May 2018
SING GEORGE L Director
Sold, plan not stated 4×
$3.73M 13,000 at 286.62
10.2%
9 May 2018
SING GEORGE L Director
Sold, plan not stated
$2.00M 7,000 at 285.29
5.2%
19 Mar 2018
Sold, plan not stated
$700.04K 2,000 at 350.02
14.3%
14 Mar 2018
Sold, plan not stated
$680.00K 2,000 at 340.00
14.3%
9 Feb 2018
Sold, plan not stated
$325.60K 1,000 at 325.60
7.7%
5 Oct 2017
BROWN MICHAEL S Director
Sold, plan not stated
$712.50K 1,500 at 475.00
100%
Sold half or more
29 Sep 2017
BAKER CHARLES A Director
Sold, plan not stated
$900.00K 2,000 at 450.00
18.2%
6 Sep 2017
Landry Robert E SVP Finance & CFO
Sold, plan not stated 5×
$235.87K 474 at 497.62
6.3%
5 Sep 2017
Landry Robert E SVP Finance & CFO
Sold, plan not stated 2×
$94.70K 189 at 501.06
2.4%
31 Aug 2017
Landry Robert E SVP Finance & CFO
Sold, plan not stated 4×
$210.69K 427 at 493.43
5.7%
25 Aug 2017
Sanofi 10% owner · indirect
Bought 9×
$34.84M 72,378 at 481.36
0.3%
First buy on file
24 Aug 2017
Sanofi 10% owner · indirect
Bought 14×
$51.01M 105,820 at 482.04
0.4%
First buy on file
23 Aug 2017
Sanofi 10% owner · indirect
Bought 5×
$29.02M 60,595 at 478.98
0.3%
First buy on file
23 Aug 2017
Landry Robert E SVP Finance & CFO
Sold, plan not stated 4×
$222.98K 468 at 476.45
6.2%
22 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 14×
$15.26M 31,944 at 477.64
8.8%
21 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated 3×
$11.41M 24,269 at 470.32
6.3%
18 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated
$1.36M 2,900 at 470.15
0.7%
17 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated
$613.35K 1,305 at 470.00
0.3%
16 Aug 2017
VAGELOS P ROY Chairman of the Board
Sold, plan not stated
$5.17M 10,986 at 470.17
2.7%
8 Aug 2017
Landry Robert E SVP Finance & CFO
Sold, plan not stated 4×
$248.37K 526 at 472.19
6.9%
22 Jun 2017
STAHL NEIL EVP Research and Development
Sold, plan not stated 19×
$4.42M 8,306 at 532.55
25.8%
22 Jun 2017
Aberman Michael S SVP Strategy Investor Relation
Sold, plan not stated 12×
$1.21M 2,269 at 532.42
32.6%
20 Jun 2017
BROWN MICHAEL S Director
Sold, plan not stated
$1.50M 3,000 at 500.00
100%
Sold half or more
20 Jun 2017
Sold, plan not stated
$500.01K 1,000 at 500.01
7.1%
16 Jun 2017
Terifay Robert J EVP Commercial
Sold, plan not stated
$9.90M 21,147 at 468.19
47.6%
15 Jun 2017
STAHL NEIL EVP Research and Development
Sold, plan not stated 12×
$4.01M 8,567 at 468.45
26.3%
12 Jun 2017
BROWN MICHAEL S Director
Sold, plan not stated 6×
$948.89K 2,000 at 474.45
100%
Sold half or more
9 Jun 2017
Sold, plan not stated
$482.55K 1,000 at 482.55
7.1%
2 Jun 2017
Sanofi 10% owner · indirect
Bought 15×
$65.06M 136,050 at 478.17
0.6%
First buy on file
2 Jun 2017
STAHL NEIL EVP Research and Development
Sold, plan not stated 12×
$1.35M 2,812 at 479.49
10.5%
25 May 2017
VAGELOS P ROY Chairman of the Board · indirect
Sold, plan not stated 3×
$4.26M 9,295 at 458.14
10.0%
12 May 2017
BROWN MICHAEL S Director
Sold, plan not stated
$1.35M 3,000 at 450.00
100%
Sold half or more
29 Mar 2017
BROWN MICHAEL S Director
Sold, plan not stated
$400.00K 1,000 at 400.00
100%
Sold half or more
11 Jan 2017
Sanofi 10% owner · indirect
Bought 18×
$32.27M 87,298 at 369.71
0.4%
First buy on file
12 Dec 2016
BAKER CHARLES A Director
Sold, plan not stated 5×
$1.18M 3,000 at 392.02
25.0%
15 Nov 2016
RYAN ARTHUR F Director
Sold, plan not stated
$858.68K 2,000 at 429.34
5.2%
14 Nov 2016
Sold, plan not stated
$956.25K 2,125 at 450.00
14.0%
Showing 401–445 of 445. ← Newer Page 9 of 9